Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 89

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 89
---
,703 Stockholders’ deficit:  Series A Preferred Stock, $0.0001 par value; 134,904.563 and no shares authorized as of December 31, 2024 and December 31, 2023, respectively; 120,790.402 and no shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively— — Series B Preferred Stock, $0.0001 par value; 437,927 and no shares authorized as of December 31, 2024 and December 31, 2023, respectively; 437,927 and no shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively— — Preferred stock, $0.0001 par value; 9,427,168.437 and 9,451,625 shares authorized as of December 31, 2024 and December 31, 2023, respectively;  no shares issued and outstanding as of December 31, 2024 and December 31, 2023— — Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 25,767,369 and 5,397,597 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively3 1 Additional paid-in capital689,887 179,062 Accumulated deficit(692,071)(614,647)Accumulated other comprehensive loss(4,621)(4,600)Total stockholders’ deficit(6,802)(440,184)Total liabilities, convertible preferred stock, and stockholders’ deficit$435,023 $305,050 

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Cartesian Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands, except share and per share data)

 Year Ended December 31,20242023Revenue:Collaboration and license revenue$38,275 $26,004 Grant revenue638 — Total revenue38,913 26,004 Operating expenses:Research and development45,105 71,260 General and administrative30,126 40,